Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1113 results for criteria

  1. Cutting-edge robotic surgery gets green light as 11 systems are recommended

    Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.

  2. Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment

    Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.

  3. HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases

    Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.

  4. Changes approved to the routing criteria for highly specialised technologies

    At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.

  5. Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment

    We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life.

  6. Learn more about the proposed changes to our routing criteria for highly specialised technologies

    News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December...

  7. Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria

    NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.

  8. New price deal paves way for NICE approval of treatment for rare genetic condition

    A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.

  9. Improvements for people with acute kidney injury in updated quality standard

    An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.

  10. NICE recommends 8 digitally enabled therapies to treat depression and anxiety

    Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance.

  11. Digital mental health tech for children and young people recommended by NICE in first rapid healthtech guidance

    Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety or low mood have been recommended for use in the NHS.

  12. Seven technologies recommended to help people with non-specific low back pain

    People with non-specific low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended in draft guidance.

  13. Two technologies to provide digital services for people with COPD

    More people with chronic obstructive pulmonary disease (COPD) could soon access rehabilitation programmes after draft guidance from NICE conditionally recommended two technologies to provide digital services to NHS patients.

  14. NICE and NHS England announce plan to enable innovative tech to be adopted quicker

    NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.

  15. NICE's flexibility in evaluation of new health tech and fairer patient access

    Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.